It's clear that Evamist sales have failed to match expectations. How much of that is due to KV's distractions and/or marketing is unclear, but it is likely to reduce the value of any Ellavie deal.
Still, Evamist + Ellavie + the Eli Lilly vet product will give Acrux a royalty income in the near future, which leaves it one up on (say) Chemgenex or Peplin, which have similar market caps and lead products in phase III trials.
It would be good to see Acrux finding some new partners, though, to progress the rest of its pipeline.
Add to My Watchlist
What is My Watchlist?
